# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Synovial sarcoma

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 30 results.
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
Status: Recruiting
Last Changed: Nov 18, 2020
First Received: Oct 31, 2019
Disease(s): Synovial Sarcoma
Intervention(s): Ramucirumab, Gemcitabine, Docetaxel
Locations: Childrens Hospital of Alabama, Birmingham, Alabama, United States
Phoenix Childrens Hospital, Phoenix, Arizona, United States
Childrens Hospital of Los Angeles, Los Angeles, California, United States
UCLA Medical Center, Los Angeles, California, United States
Childrens Hospital of Orange County, Orange, California, United States
... and 50 other locations.
Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma
Status: Recruiting
Last Changed: Oct 06, 2020
First Received: Nov 25, 2019
Disease(s): Relapsed or Refractory Synovial Sarcoma
Intervention(s): OTSA101-DTPA-111In, OTSA101-DTPA-90Y
Locations: Osaka International Cancer Institute, Osaka, Japan
Cancer Institute Hospital of JFCR, Tokyo, Japan
National Cancer Center Hospital, Tokyo, Japan
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Status: Recruiting
Last Changed: Oct 05, 2020
First Received: Aug 05, 2019
Disease(s): Synovial Sarcoma, Myxoid Liposarcoma
Intervention(s): ADP-A2M4
Locations: City of Hope, Duarte, California, United States
Stanford Cancer Center, Palo Alto, California, United States
University of Colorado, Aurora, Colorado, United States
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
... and 21 other locations.
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
Status: Recruiting
Last Changed: Oct 29, 2020
First Received: Jan 11, 2017
Disease(s): Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
Intervention(s): AL3818, Dacarbazine, AL3818 or placebo
Locations: Mayo Clinic Arizona, Phoenix, Arizona, United States
University of California Los Angeles, Los Angeles, California, United States
Sarcoma Oncology Center, Santa Monica, California, United States
Stanford Medicine Cancer Institute, Stanford, California, United States
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
... and 16 other locations.
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Status: Recruiting
Last Changed: May 08, 2020
First Received: Nov 11, 2015
Disease(s): Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary
Intervention(s): Tazemetostat
Locations: Children's Hospital of Los Angeles, Los Angeles, California, United States
University of California San Francisco - Benioff Children's Hospital, San Francisco, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Children's National Medical Center, Washington, District of Columbia, United States
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
... and 31 other locations.
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Status: Recruiting
Last Changed: Oct 22, 2020
First Received: Nov 11, 2015
Disease(s): Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features, Synovial Sarcoma, INI1-negative Tumors, Malignant Rhabdoid Tumor of Ovary, Renal Medullary Carcinoma, Epithelioid Sarcoma, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Any Solid Tumor With an EZH2 GOF Mutation
Intervention(s): Tazemetostat
Locations: University of California San Francisco, San Francisco, California, United States
University of Colorado Denver, Aurora, Colorado, United States
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Northwestern Memorial Hospital, Chicago, Illinois, United States
Massachusetts General Hospital - Cancer Center, Boston, Massachusetts, United States
... and 28 other locations.
The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma
Status: Recruiting
Last Changed: Jul 14, 2020
First Received: Apr 22, 2020
Disease(s): Sarcoma, Soft Tissue
Intervention(s): Sintilimab, Doxorubicin Hydrochloride, Ifosfamide
Locations: Fudan University, Cancer Hospital, Shanghai, Shanghai, China
Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma
Status: Recruiting
Last Changed: Mar 23, 2020
First Received: Mar 01, 2018
Disease(s): HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma, Recurrent Synovial Sarcoma
Intervention(s): Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, Dendritic Cell-targeting Lentiviral Vector ID-LV305, Immunotherapeutic Combination Product CMB305
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Soft Soft Tissue Sarcomas
Status: Recruiting
Last Changed: May 21, 2020
First Received: Sep 13, 2018
Disease(s): Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma, Advanced Soft Tissue Sarcoma, Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Soft Tissue Sarcoma, Refractory Leiomyosarcoma, Refractory Myxoid Liposarcoma, Refractory Round Cell Liposarcoma, Refractory Soft Tissue Sarcoma, Refractory Synovial Sarcoma, Refractory Undifferentiated Pleomorphic Sarcoma, Advanced Leiomyosarcoma, Advanced Synovial Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma
Intervention(s): Itacitinib, Laboratory Biomarker Analysis
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Status: Recruiting
Last Changed: Oct 22, 2020
First Received: Jan 08, 2016
Disease(s): Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Synovial Sarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Fallopian Tube Carcinoma, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Synovial Sarcoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Unresectable Melanoma, Unresectable Ovarian Carcinoma, Unresectable Synovial Sarcoma
Intervention(s): Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis, Leukapheresis, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Locations: Roswell Park Cancer Institute, Buffalo, New York, United States